Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1878, Issue 6, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2023.188990
Keywords
Cancer; Gut microbiota; Dysbiosis; Fecal microbiota transplantation; Probiotics; Prebiotics
Categories
Ask authors/readers for more resources
Treatment resistance and adverse effects are important issues in cancer patient management. The use of microbiome in oncology is showing promising results. Favorable bacterial species and gut diversity are associated with increased treatment efficacy, while alterations in gut microbiome contribute to intestinal dysbiosis and treatment-induced toxicity.
Treatment resistance, together with acute and late adverse effects, represents critical issues in the management of cancer patients. Promising results from preclinical and clinical research underline the emerging trend of a microbiome-based approach in oncology. Favorable bacterial species and higher gut diversity are associated with increased treatment efficacy, mainly in chemo- and immunotherapy. On the other hand, alterations in the composition and activity of gut microbial communities are linked to intestinal dysbiosis and contribute to high treatment-induced toxicity. In this Review, we provide an overview of studies concerning gut microbiota modulation in patients with solid and hematologic malignancies with a focus on probiotics, prebiotics, postbiotics, and fecal microbiota transplantation. Targeting the gut microbiome might bring clinical benefits and improve patient outcomes. However, a deeper understanding of mechanisms and large clinical trials concerning microbiome and immunological profiling is warranted to identify safe and effective ways to incorporate microbiota-based interventions in routine clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available